血栓前状态分子标志物在2型糖尿病微血管病变中的变化

The changes of markers to prethrombotics tate in patients with type 2 diabetes microangiopathy

目的:探讨凝血与纤溶功能变化在2型糖尿病微血管病变中的临床意义。方法:采用发色底物法测定正常对照组(30例)、无微血管病变组(62例)、微血管病变组(65例)纤溶酶原激活物抑制物-1(PAI-1)活性,采用免疫浊度法测定分组纤维蛋白原(FIB)水平,比较3组PAI-1及FIB水平。结果:糖尿病微血管病变组血浆PAI-1和FIB水平明显高于无微血管病变组及正常对照组(P<0.01),且糖尿病无微血管病变组血浆PAI-1和FIB水平高于正常对照组(P<0.05)。结论:2型糖尿病患者存在血液的高凝及低纤溶状态,在发生2型糖尿病微血管病变后更为明显,检测2型糖尿病患者血浆中PAI-1和FIB水平对糖尿病微血管病变的预防和治疗具有一定的临床意义。

Objective： To investigate the changes of plasma coagulation and fibrinolysis parameters in type 2 diabetic microangiopathy. Methods： The plasminogen activator inhibitor-1 （PAI-1） and plasma fibrinogen （FIB） in type 2 diabetes were measured. Results： In diabetic group, the levels of PAI 1 and FIB were signifiantly higher in patients with microangiopathy than those without diabetic microangiopathy （P 〈0.01）. The levels of PAI-1 and FIB were signifiantly increased in both groups of patients with microangiopathy and withoutmicroangiopathy compared with controls （P 〈0.05）. Conclusion： The condition of high coagulation and low fibrinolytic base was in type 2 diabetes mellitus, and even more serious in diabetic microangiopathy It＇s critical to measure the levels of prethrombotic state PAI-1 and FIB for prevention and treatment in type 2 diabetic microangiopathy.